Pfizer Inc (PFE)

$26.92 -0.30 (-1.10%)
Market Cap 153.07B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.43
Forward PE 9.14
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 27,882,300
Avg Vol 42,996,574
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 8%
Beta 0.43
Analysts Sell
Price Target $28.94

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
edlu77
edlu77 Apr. 13 at 3:18 PM
$PFE $27 is poison
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 3:06 PM
$PFE another analyst upgrade and another day of red
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 2:54 PM
$PFE POS as per usual
0 · Reply
RichMitch
RichMitch Apr. 13 at 2:52 PM
$REPL $PFE $MRNA $BMY That $1.55 was delicious
0 · Reply
traderheadnyc
traderheadnyc Apr. 13 at 2:39 PM
$PFE got price target raise to 28 but I had hoped for $30 - Collecting my dividend but very disappointed
0 · Reply
Brad_Gonzalez_46
Brad_Gonzalez_46 Apr. 13 at 2:30 PM
$PFE lagging still needs a shift in sentiment buyers not aggressive yet
0 · Reply
RichMitch
RichMitch Apr. 13 at 1:54 PM
$REPL hmm 🤔 $PFE $MRNA $BMY
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 1:31 PM
$PFE hell yeah more red!
0 · Reply
NomadiCapital
NomadiCapital Apr. 13 at 12:56 PM
$PFE Filled our weekly gap last week. The last 2 gap fills result in bounces weeks later. Dividend coming in May. This week is the 3rd week of the 3W candle. Average 3W range -> Statistics say this week likely stays above $26 but below $29.50
0 · Reply
DragonAlgo
DragonAlgo Apr. 13 at 11:08 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-04-17 | Strike: $27.00 | Type: PUT Option Plan (premium): Entry: $0.36 Stop: $0.26 TP1: $0.47 TP2: $0.61 TP3: $0.86 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
Latest News on PFE
Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 10, 2026, 11:00 PM EDT - 2 days ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 9, 2026, 10:00 AM EDT - 4 days ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Why Is Pfizer Stock Dropping Tuesday?

Apr 7, 2026, 1:54 PM EDT - 5 days ago

Why Is Pfizer Stock Dropping Tuesday?

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 10 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 11 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 12 days ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 14 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 20 days ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 20 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mar 23, 2026, 10:35 AM EDT - 21 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 21 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 21 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 21 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 21 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 21 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 22 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 23 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 25 days ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 25 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 27 days ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 27 days ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 5 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 5 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 5 weeks ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 5 weeks ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 5 weeks ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 5 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 6 weeks ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 6 weeks ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 6 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 6 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 6 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 7 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 7 weeks ago

Is There 25% Downside For Pfizer Stock?

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 7 weeks ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 2 months ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 2 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 2 months ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 2 months ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 2 months ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 2 months ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 2 months ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 2 months ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 2 months ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 2 months ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 2 months ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 2 months ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 2 months ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

edlu77
edlu77 Apr. 13 at 3:18 PM
$PFE $27 is poison
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 3:06 PM
$PFE another analyst upgrade and another day of red
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 2:54 PM
$PFE POS as per usual
0 · Reply
RichMitch
RichMitch Apr. 13 at 2:52 PM
$REPL $PFE $MRNA $BMY That $1.55 was delicious
0 · Reply
traderheadnyc
traderheadnyc Apr. 13 at 2:39 PM
$PFE got price target raise to 28 but I had hoped for $30 - Collecting my dividend but very disappointed
0 · Reply
Brad_Gonzalez_46
Brad_Gonzalez_46 Apr. 13 at 2:30 PM
$PFE lagging still needs a shift in sentiment buyers not aggressive yet
0 · Reply
RichMitch
RichMitch Apr. 13 at 1:54 PM
$REPL hmm 🤔 $PFE $MRNA $BMY
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 13 at 1:31 PM
$PFE hell yeah more red!
0 · Reply
NomadiCapital
NomadiCapital Apr. 13 at 12:56 PM
$PFE Filled our weekly gap last week. The last 2 gap fills result in bounces weeks later. Dividend coming in May. This week is the 3rd week of the 3W candle. Average 3W range -> Statistics say this week likely stays above $26 but below $29.50
0 · Reply
DragonAlgo
DragonAlgo Apr. 13 at 11:08 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-04-17 | Strike: $27.00 | Type: PUT Option Plan (premium): Entry: $0.36 Stop: $0.26 TP1: $0.47 TP2: $0.61 TP3: $0.86 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 13 at 10:39 AM
$IDYA daro/crizo combo is an easy choice for patients, docs and payors. $PFE should consider taking the entire company after these results.
0 · Reply
JuggernautRaider
JuggernautRaider Apr. 13 at 12:10 AM
$SLS SELLAS may double soon if the phase 3 is positive. Will it be bought shortly thereafter? My old employer $BMY seems like a likely acquirer given Onurig & their need for hem/onc assets. Who else makes sense? $GILD ? $PFE ?
1 · Reply
Doozio
Doozio Apr. 11 at 10:41 PM
$PFE chop chop huckleberries…… 🐒🍌🧠⏰♾️????
1 · Reply
TalkMarkets
TalkMarkets Apr. 11 at 4:40 PM
#BristolMyers Gains 10% Year To Date: Should You Buy, Sell Or Hold The #Stock? $BMY $MRK $PFE https://talkmarkets.com/article/bristol-myers-gains-10-year-to-date-should-you-buy-sell-or-hold-the-stock-1775925607
0 · Reply
josegodoy
josegodoy Apr. 11 at 4:22 PM
$PFE liking this
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 11 at 2:27 PM
$OMER the pharma not in cash are going to struggle $PFE $SANOFI.NSE $RGC $OGN
0 · Reply
StockMacroView
StockMacroView Apr. 11 at 8:58 AM
$PFE Risk-averse with a long-term lens? Pfizer is flashing a major buy signal. This isn't for the thrill-seekers; it’s for the disciplined investors building a fortress portfolio. With steady medium-to-long-term upside and limited volatility, $PFE is the ultimate "sleep-well-at-night" play for your core holdings. 👉Click to view @StockMacroView for timely updates amid the volatility.
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 10 at 11:31 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names . $DE $ARM $PFE $NVO
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 11:19 PM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-04-17 | Strike: $27.00 | Type: PUT Option Plan (premium): Entry: $0.36 Stop: $0.26 TP1: $0.47 TP2: $0.62 TP3: $0.88 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
stockjusthave
stockjusthave Apr. 10 at 10:55 PM
$PFE just for fun This is last year march Pfizer price target raised to $28 from $27 at BofA Intellectia AI https://intellectia.ai › news › stock › pfizer-bofa-global-... Mar 26, 2025 — Price Target Adjustment: BofA increased Pfizer's price target to $28 from $27 while maintaining a Neutral rating, citing solid Q2 results and stable revenue ...Read more Today MarketBeat https://www.marketbeat.com › instant-alerts › pfizer-ny... 7 hours ago — Morgan Stanley raised its price target on Pfizer from $27 to $28 and maintained an "equal weight" rating, implying roughly a 3.7% upside. · The ...Read more only year changes that 1$ target remains the same.
0 · Reply
Typecheck
Typecheck Apr. 10 at 8:01 PM
$PFE close near the low of the day. My gut feeling is that more drop to come next week.
0 · Reply
AFJuvat
AFJuvat Apr. 10 at 7:18 PM
$PFE R.I.P. BOURLA
0 · Reply